-
FDA sets May 2027 decision date on AMT-130 gene therapy for HD
4 min read
Latest News
-
October 2026: This Month in Huntington’s Disease Research
4 min read
From sticky thoughts and pigs that model HD to DNA repair and promising drug trial results, October brought fresh insights into HD. Here’s what you might have missed!
-
New experiments clarify the role of SIRT1 in HD – or do they?
7 min read
Work from multiple labs suggests activating a protein called SIRT1 might help HD, but the picture is still confusing
-
Bone marrow transplantation in Huntington's Disease
5 min read
Bone marrow transplant protects HD mice from some symptoms, suggesting the immune system may be an important target
-
2011 – a year in Huntington's disease research
8 min read
Looking back at a year in Huntington's disease research – and the first year of HDBuzz
-
Gene therapy meets stem cells in liver disease success
6 min read
Scientists combine gene therapy and stem cells to correct a genetic liver disease. Could this combo be retooled for H
-
Chinese Huntington’s Disease Network launched
5 min read
Chinese Huntington’s Disease Network launched. Good news for China, good news for the global HD community
-
HDAC inhibitor drug protects memory in HD mice
8 min read
CBP, a gene-switching protein, protects memory in HD mice; 'histone deacetylase inhibitor' drug mimics its effects
-
Turning down the volume with dantrolene helps HD mice
5 min read
Dantrolene, an muscle-relaxer drug already on the market, helps HD mice by reducing cellular calcium levels
-
TRACK-HD reveals changes in HD mutation carriers, empowering future trials
7 min read
Follow-up data from TRACK-HD study proves that we have the tests we need to successfully run drug trials for HD
-
Huntexil hits the headlines again
3 min read
Huntexil makes headlines with science journal article, but nothing's changed: another trial is needed before approval
-
New antibody reveals dangerous parts of huntingtin protein
6 min read
A new antibody lets scientists identify neurons that are going to die after producing mutant huntingtin
HDBuzz Trial Tracker
FDA accepts BLA for Priority Review, with a target decision date of 1 May 2027.
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
